However, no enhanced radiosensitization was observed in the DNA-PK deficient M059J GBM cell line demonstrating the specificity of the drug to its target.38 Although effective in preclinical evaluation, there is a substantial risk that inhibition of DNA-PK catalytic activity will severely exacerbate normal brain toxicity. Here, PRKDC is linked to glioblastoma.